Use of Bortezomib for Prevention and Treatment of Rejection in Sensitized Patients.

Hartono C, Lubetzky M, Aull MJ, Saal S, Figueiro J, Kapur S, Dadhania D.

Clinical Transplants 2009, Chapter 55

Abstract

We report 2 cases of sensitized patients who were successfully treated with bortezomib therapy resulting in reduction of donor-specific antibodies (DSA). Our cases illustrate the synergistic effects of combination therapy that includes bortezomib on prevention and treatment of AMR in highly sensitized patients. Moving forward, long-term data on sensitized patients treated with bortezomib are needed to fully evaluate the impact of this therapy.